<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910441</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237AIN03</org_study_id>
    <nct_id>NCT01910441</nct_id>
  </id_info>
  <brief_title>Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients</brief_title>
  <acronym>VARIABLE</acronym>
  <official_title>A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India (DCGI)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on
      glucose variability in T2DM patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean amplitude of glycemic excursions (MAGE) using continuous glucose monitoring system (CGMS)</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>MAGE has been shown to be independent of mean glycaemia and the greater the MAGE, the higher the glycaemic fluctuations. MAGE will be calculated from the arithmetic mean of the differences between consecutive peaks and nadirs; measurement in the peak-to-nadir or nadir-to-peak direction is determined by the first qualifying excursion (defined as exceeding the value of one standard deviation of the blood glucose for the same 24-hour period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent glycosylated hemoglobin reduction from baseline at 16 weeks</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to glycemic control assessed through CGMS</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glycemic control is defined as hypoglycemic range/hyperglycemic range and ideal glycemic range&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching the glycemic targets after 16 weeks treatment, in the overall study population</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients reaching the glycemic target of (i) HbA1c ≤ 6.5% and (ii) HbA1c ≤ 7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unrecognized hypoglycemia events recognized by CGMS</measure>
    <time_frame>6 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group A: Vildagliptin plus metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Glimepiride plus metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin 50 mg twice daily</description>
    <arm_group_label>Group A: Vildagliptin plus metformin</arm_group_label>
    <other_name>Group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride 1-6 mg once daily</description>
    <arm_group_label>Group B: Glimepiride plus metformin</arm_group_label>
    <other_name>Group B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin (1000-1500 mg daily)</description>
    <arm_group_label>Group A: Vildagliptin plus metformin</arm_group_label>
    <arm_group_label>Group B: Glimepiride plus metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have given written informed consent to participate in the study.

          2. Type 2 Diabetes Mellitus patients either Male or female from 18 - 75 years of age
             (both inclusive).

          3. Patients who are uncontrolled on metformin monotherapy for at least past 4 weeks
             (1000-1500 mg daily and HbA1c &gt; 7.5 - 9%).

          4. Patients with HbA1C levels within the range &gt; 7.5% - 9%. (If a past value is
             available within the last 12 weeks, it would be considered acceptable provided it was
             obtained after at least 4 weeks of metformin therapy 1000-1500 mg daily).

        Exclusion Criteria:

          1. Age &gt; 75 years ; BMI &lt;22 or &gt;40 kg/m2

          2. Patients who are on Insulin therapy at the time of study entry.

          3. Type 1 Diabetes Mellitus patients.

          4. Patients with severe renal (creatinine clearance &lt; 50 ml/min) or hepatic impairment
             (including pre-treatment ALT or AST &gt; 3 x ULN).

             Creatinine clearance will be estimated from serum creatinine using Cockcroft-Gault
             formula (Cockcroft and Gault, 1976)

          5. Patients with contraindications as mentioned in the Summary of Product
             Characteristics (SPCs) for vildagliptin, metformin, glimepiride, vildagliptin plus
             metformin and glimiperide plus metformin.

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 096</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110076</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 040</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625 020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Varanasi</city>
        <state>Uttar Pradesh</state>
        <zip>221 005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkatta</city>
        <state>West Bengal</state>
        <zip>700 027</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bhubaneswar</city>
        <zip>751005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <zip>641009</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <zip>641018</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110 017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus, Glycemic variability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
